drugset / Trial / NCT02109627
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Phase 1
Terminated
17 enrolled
C. Babis Andreadis
AVEO Pharmaceuticals, Inc. · collabGateway for Cancer Research · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard treatment for AML, is safe to give to patients and to determine the best dose to give. The study doctors want to see what effects, good and/or bad, the study drug has on subjects and their AML. The study will look at what side effects subjects may have and how subjects feel after receiving the study drug.
Timeline
- Start
- 2015-05-01
- Primary completion
- 2019-12-02
- Completion
- 2019-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ficlatuzumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Ficlatuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |